secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001104659-26-039935
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics Biotech enters ATM agreement for up to $75M common stock offering
----------------------------------------------------------------------------

- Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
- Proceeds to fund clinical development of pelareorep, R&D, operating costs, and general corporate purposes.
- Jefferies will receive a commission of 3.0% of gross proceeds; company also reimburses certain expenses.
- Shares sold under shelf registration effective April 3, 2026; prospectus supplement filed April 6, 2026.
- Company is not obligated to sell any shares; either party may terminate on ten trading days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926039935/0001104659-26-039935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926039935/tm2610715d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-039935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer